Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Eiger Biopharmaceuticals
Eiger Biopharmaceuticals
(EIGR)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Zokinvy
Lonafarnib
2022-07-18
2023-2024
Progeria
,
Laminopathies
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Lonafarnib
progeria
,
chronic hepatitis d
,
hepatitis d
,
hepatitis b
,
laminopathies
Avexitide
healthy volunteers/patients
,
bariatric surgery
,
insulin resistance
,
hyperglycemia
,
nutrition disorders
,
gastric emptying
,
digestive system physiological phenomena
,
gastrointestinal motility
,
gastric bypass
,
gastrectomy
,
gestational diabetes
,
diabetes mellitus
,
congenital hyperinsulinism
,
hyperinsulinism
,
nesidioblastosis
,
type 1 diabetes mellitus
,
dyspepsia
,
genetic predisposition to disease
,
hypoglycemia
,
type 2 diabetes mellitus
,
obesity
,
glucose intolerance
,
insulin secretion
,
prediabetic state
,
glucose metabolism disorders
,
metabolic diseases
,
kidney diseases
,
stomach neoplasms
,
dumping syndrome
,
morbid obesity
,
heart diseases
,
exploratory behavior
,
appetite regulation
,
postural orthostatic tachycardia syndrome
Clemizole
hepatitis c
,
hepatitis
,
hepatitis a
Ubenimex
hypertension
,
pulmonary arterial hypertension
,
familial primary pulmonary hypertension
,
lymphedema
Ebp921
hepatitis d
,
hepatitis
,
hepatitis a
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use